Compare Amylx Pharmaceuticals Inc (AMLX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $33.03, up 8.08% with a bullish technical signal. Recent stock splits (1:3 on June 25-26, 2026) reflect volatility management. The ETF has shown strong YTD performance (+12.66% as of June 8, 2026) but remains highly sensitive to NVIDIA's daily moves, evidenced by a 12% single-day drop on June 5, 2026. Technical indicators show bullish moving averages but neutral oscillators, with key resistance at $33.

Outlook: High-growth potential tied to NVIDIA's AI dominance, but leveraged structure amplifies risks. Daily resets can erode value during volatility, as seen in early 2025's 67% decline. Investors must weigh AI-driven upside against compounded losses in downtrends. Key risks include NVIDIA-specific volatility and broader semiconductor cyclicality.